TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -232 Thousand USD | 75293.75% |
| 2022 | -16 Thousand USD | -104.82% |
| 2021 | 332 Thousand USD | 2866.67% |
| 2020 | -12 Thousand USD | 45.45% |
| 2019 | -22 Thousand USD | 99.92% |
| 2018 | -27.46 Million USD | -159.06% |
| 2017 | -10.6 Million USD | 10.13% |
| 2016 | -11.79 Million USD | 5.84% |
| 2015 | -12.52 Million USD | -898.09% |
| 2014 | -1.25 Million USD | 68.49% |
| 2013 | -3.98 Million USD | -90.76% |
| 2012 | -2.08 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 96 Thousand USD | -96.84% |
| 2024 Q2 | 55 Thousand USD | -42.71% |
| 2023 Q1 | -4000.00 USD | 0.0% |
| 2023 Q4 | 3.04 Million USD | 76150.0% |
| 2023 FY | 12.03 Million USD | 75293.75% |
| 2023 Q3 | -4000.00 USD | -100.04% |
| 2023 Q2 | 8.99 Million USD | 225025.0% |
| 2022 FY | -16 Thousand USD | -104.82% |
| 2022 Q4 | -4000.00 USD | -33.33% |
| 2022 Q3 | -3000.00 USD | 25.0% |
| 2022 Q2 | -4000.00 USD | 20.0% |
| 2022 Q1 | -5000.00 USD | 98.57% |
| 2021 Q2 | -2.72 Million USD | -136000.0% |
| 2021 Q4 | -350 Thousand USD | -8650.0% |
| 2021 Q1 | -2000.00 USD | 99.91% |
| 2021 Q3 | -4000.00 USD | 99.85% |
| 2021 FY | 332 Thousand USD | 2866.67% |
| 2020 Q4 | -2.19 Million USD | -23.08% |
| 2020 Q1 | -1.99 Million USD | -4.44% |
| 2020 Q2 | -2.21 Million USD | -11.01% |
| 2020 Q3 | -1.78 Million USD | 19.52% |
| 2020 FY | -12 Thousand USD | 45.45% |
| 2019 FY | -22 Thousand USD | 99.92% |
| 2019 Q4 | -1.91 Million USD | 37.4% |
| 2019 Q2 | -2.88 Million USD | 44.65% |
| 2019 Q3 | -3.05 Million USD | -5.89% |
| 2019 Q1 | -5.21 Million USD | 52.13% |
| 2018 Q1 | -4.78 Million USD | -57.25% |
| 2018 Q4 | -10.89 Million USD | -105.03% |
| 2018 FY | -27.46 Million USD | -159.06% |
| 2018 Q3 | -5.31 Million USD | 17.96% |
| 2018 Q2 | -6.47 Million USD | -35.4% |
| 2017 Q3 | 4.73 Million USD | 289.17% |
| 2017 Q1 | -3.07 Million USD | -23.98% |
| 2017 Q2 | -2.5 Million USD | 18.53% |
| 2017 FY | -10.6 Million USD | 10.13% |
| 2017 Q4 | -3.04 Million USD | -164.25% |
| 2016 Q1 | -2.59 Million USD | 65.12% |
| 2016 FY | -11.79 Million USD | 5.84% |
| 2016 Q4 | -2.47 Million USD | -1.02% |
| 2016 Q3 | -2.45 Million USD | 42.63% |
| 2016 Q2 | -4.27 Million USD | -64.89% |
| 2015 Q2 | -29 Thousand USD | 98.27% |
| 2015 Q1 | -1.67 Million USD | -167.62% |
| 2015 FY | -12.52 Million USD | -898.09% |
| 2015 Q4 | -7.43 Million USD | -119.43% |
| 2015 Q3 | -3.38 Million USD | -11579.31% |
| 2014 Q1 | -261 Thousand USD | 78.83% |
| 2014 Q2 | 92 Thousand USD | 135.25% |
| 2014 Q3 | -492 Thousand USD | -634.78% |
| 2014 Q4 | -627 Thousand USD | -27.44% |
| 2014 FY | -1.25 Million USD | 68.49% |
| 2013 Q1 | -538 Thousand USD | 0.0% |
| 2013 Q3 | -1.61 Million USD | -171.76% |
| 2013 FY | -3.98 Million USD | -90.76% |
| 2013 Q2 | -595 Thousand USD | -10.59% |
| 2013 Q4 | -1.23 Million USD | 23.75% |
| 2012 FY | -2.08 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 237.614% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 7.2% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 57.895% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -30.337% |
| Better Therapeutics, Inc. | -2.72 Million USD | 91.499% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 83.249% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 154.884% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 98.988% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 77.288% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 96.729% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 10.425% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -340.244% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 91.702% |
| Molecular Templates, Inc. | 50.39 Million USD | 100.46% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -94.476% |
| NexImmune, Inc. | -1.02 Million USD | 77.365% |
| Orgenesis Inc. | -5.72 Million USD | 95.948% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 99.095% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -4942.382% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 100.789% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 52.49% |
| Trevena, Inc. | 1.45 Million USD | 115.945% |
| Vaxxinity, Inc. | -2.23 Million USD | 89.615% |
| Vaccinex, Inc. | -16 Million USD | 98.55% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 52.846% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 2098.277% |